Login / Signup

First-in-human study of a pharmacological duodenal exclusion therapy shows reduced postprandial glucose and insulin and increased bile acid and gut hormone concentrations.

Mark S FinemanChristine L N BryantKevin ColbertThomas H JozefiakJohn S PetersenMichael HorowitzJiten VoraChristopher K RaynerPaul WabnitzAshish Nimgaonkar
Published in: Diabetes, obesity & metabolism (2023)
GLY-200 is safe and generally well tolerated at doses of ≤2.0 g twice daily. Pharmacodynamic results mimic the biomarker signature observed after Roux-en-Y gastric bypass and duodenal exclusion devices, indicating a pharmacological effect in the proximal small intestine. This study represents the first clinical demonstration that duodenal exclusion can be achieved with an oral drug and supports further development of GLY-200 for the treatment of obesity and/or T2D.
Keyphrases
  • roux en y gastric bypass
  • weight loss
  • type diabetes
  • metabolic syndrome
  • endothelial cells
  • insulin resistance
  • stem cells
  • bariatric surgery
  • adipose tissue
  • glycemic control
  • adverse drug
  • electronic health record